TNSN07366A1 - Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie - Google Patents

Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie

Info

Publication number
TNSN07366A1
TNSN07366A1 TNP2007000366A TNSN07366A TNSN07366A1 TN SN07366 A1 TNSN07366 A1 TN SN07366A1 TN P2007000366 A TNP2007000366 A TN P2007000366A TN SN07366 A TNSN07366 A TN SN07366A TN SN07366 A1 TNSN07366 A1 TN SN07366A1
Authority
TN
Tunisia
Prior art keywords
treatment
pyridoazepine
schizophrenia
tetrahydro
ones
Prior art date
Application number
TNP2007000366A
Other languages
English (en)
Inventor
David Alan Favor
Douglas Scott Johnson
Joseph Thomas Repine
Andrew David White
Original Assignee
Warner - Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner - Lambert Company Llc filed Critical Warner - Lambert Company Llc
Publication of TNSN07366A1 publication Critical patent/TNSN07366A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Il est décrit des composés de formule 1 dans laquelle G, D, A, Q, Y, Z et R1 à R10 sont définis dans le présent mémoire. Il est proposé également des descriptions de procédés pour la préparation des composés de formule 1, les intermédiaries utilisés dans leur préparation, et des compositions pharmaceutiques contenant ces composés, et leur utilisation dans le traitement de troubles du système nerveux central et d'autres troubles.
TNP2007000366A 2005-04-01 2007-09-28 Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie TNSN07366A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66744705P 2005-04-01 2005-04-01
PCT/IB2006/000900 WO2006103559A1 (fr) 2005-04-01 2006-03-20 Tetrahydro-pyridoazepin-8-ones et composes voisins utiles pour le traitement de la schizophrenie

Publications (1)

Publication Number Publication Date
TNSN07366A1 true TNSN07366A1 (fr) 2008-12-31

Family

ID=36763625

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000366A TNSN07366A1 (fr) 2005-04-01 2007-09-28 Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie

Country Status (25)

Country Link
US (1) US20060234997A1 (fr)
EP (1) EP1869041A1 (fr)
JP (1) JP4109709B1 (fr)
KR (1) KR20070112228A (fr)
CN (1) CN101189237A (fr)
AP (1) AP2007004160A0 (fr)
AR (1) AR053835A1 (fr)
AU (1) AU2006228426A1 (fr)
BR (1) BRPI0607918A2 (fr)
CA (1) CA2603049A1 (fr)
CR (1) CR9407A (fr)
DO (1) DOP2006000071A (fr)
EA (1) EA200701856A1 (fr)
GT (1) GT200600130A (fr)
IL (1) IL185770A0 (fr)
MA (1) MA29989B1 (fr)
MX (1) MX2007012083A (fr)
NL (2) NL1031489C2 (fr)
NO (1) NO20075477L (fr)
PE (1) PE20061196A1 (fr)
TN (1) TNSN07366A1 (fr)
TW (1) TW200714282A (fr)
UY (1) UY29447A1 (fr)
WO (1) WO2006103559A1 (fr)
ZA (1) ZA200708033B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116265A1 (fr) * 2006-03-31 2007-10-18 Pfizer Products Inc. Procede de fabrication d'un compose de tetrahydro-pyridoazepin-8-one
US8674790B2 (en) 2009-12-28 2014-03-18 Seiko Epson Corporation Surface acoustic wave device, oscillator, module apparatus
WO2012003418A2 (fr) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
RU2712455C1 (ru) 2016-01-15 2020-01-29 Пфайзер Инк. 6,7,8,9-тетрагидро-5h-пиридо[2,3-d]азепиновые лиганды дофаминовых рецепторов d3
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
DK3552017T3 (da) 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer
WO2022212538A1 (fr) * 2021-03-31 2022-10-06 Blueprint Medicines Corporation Composés pyrimidines condensés avec la diazépanone, compositions et leurs applications médicales
WO2023137035A1 (fr) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Formes cristallines de ((s)-5-benzyl-n-(5-méthyl-4-oxo-2, 3,4,5- tétrahydropyrido [3,2-b] [l,4]oxazépin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd Piperazine derivatives their preparation and pharmaceutical compositions containing them
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
FR2699918B1 (fr) * 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
CN101189237A (zh) 2008-05-28
CA2603049A1 (fr) 2006-10-05
US20060234997A1 (en) 2006-10-19
GT200600130A (es) 2007-02-14
NL1033562C2 (nl) 2007-10-23
TW200714282A (en) 2007-04-16
DOP2006000071A (es) 2006-10-15
BRPI0607918A2 (pt) 2009-10-20
EA200701856A1 (ru) 2008-02-28
NL1031489C2 (nl) 2007-04-02
KR20070112228A (ko) 2007-11-22
NO20075477L (no) 2007-12-13
AU2006228426A1 (en) 2006-10-05
MX2007012083A (es) 2007-11-20
NL1033562A1 (nl) 2007-06-21
UY29447A1 (es) 2006-10-31
IL185770A0 (en) 2008-01-06
ZA200708033B (en) 2008-11-26
AP2007004160A0 (en) 2007-10-31
EP1869041A1 (fr) 2007-12-26
JP2008534574A (ja) 2008-08-28
AR053835A1 (es) 2007-05-23
MA29989B1 (fr) 2008-12-01
NL1031489A1 (nl) 2006-10-03
CR9407A (es) 2008-01-29
PE20061196A1 (es) 2006-12-16
WO2006103559A1 (fr) 2006-10-05
JP4109709B1 (ja) 2008-07-02

Similar Documents

Publication Publication Date Title
MA29989B1 (fr) Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN05250A1 (fr) Pyrimidinones substituees
MA29429B1 (fr) Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
TN2009000471A1 (fr) Composes amino-heterocycliques
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA26722A1 (fr) Nouveaux composes et medicaments les contenant
TNSN07380A1 (fr) [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1
MA26729A1 (fr) Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA30027B1 (fr) [ (1h- indol- 5 -yl) -heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes utilises en tant que ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs